Zoticon's management team is comprised of pharmaceutical and biotech business development experts and experienced investment bankers located in the US, Europe, and Israel. Zoticon's management team includes:
Asher has extensive biotech operating experience-- having started several biotech Companies including Intelligene and EvoRx. Both of these companies were formed around technologies which he invented. Intelligene was one of the pioneering biotech companies dealing with molecular evolution and attracted venture capital from the top international venture firms including Walden Investments, Advent and Rothschild Venture Capital. The technology was acquired by Genetico where it is actively being developed. EvoRx was founded together with Nobel Prize Winners: Arthur Kornberg and Roger Kornberg who is the head of Structural Biology at Stanford University. Jim Manuso, the current CEO of the successful, publicly traded company, Supergen, located in California was also involved in its formation. Asher has authored over 23 patents in the field of biotechnology and was a Managing Member in Molecular Intelligence, a biotechnology advisory company. Prior to founding Zoticon, he served for the past two years as a Managing Director at Paramount Biocapital, which is a top rated venture fund for in-licensing biotechnology transactions. His responsibility at Paramount included managing Paramount’s European office.
Robert was Managing Director at the Trout Group, a global investor relations and strategic advisory service dedicated solely to the life science industry. Prior to his work for Trout, he was a Senior Vice President at Gerard Klauer Mattison, a research and investment-banking firm. He last managed GKM’s European Corporate Finance divisions as well as international venture capital opportunities. He has completed over $2 billion in financing and advisory work and opened GKM's first international office.
Dr. Rozencweig is a medical oncologist with more than 40 years of experience and accumulated expertise in clinical trials and anti-cancer drug development in academia, at the National Cancer Institute and in the pharmaceutical industry.
Dr. Rozencweig has a proven track record in global drug development leadership, having served in various senior leadership positions in worldwide clinical R&D, strategic planning, strategic marketing, portfolio management and portfolio development at Bristol-Myers Squibb . He built and led the BMS clinical research group that developed all the NCE’s (including carboplatin and Taxol) that BMS brought to market in the area of cancer from 1983 to 2001.
Dr Rozencweig has also held senior management positions in a number of small US and international biotechnology companies.
Dr. Lloyd is a leading regulatory expert with over 20 years of big pharma experience in global regulatory affairs and quality assurance.
Dr. Lloyd’s employment history includes Sr. Vice President of Global Regulatory Affairs and Drug Safety as well as Vice President, Regulatory Affairs-Late Development at ImClone Systems Inc., a wholly-owned subsidiary of Eli Lilly as well as Vice President, Worldwide Regulatory Affairs and Quality Compliance for GPC Biotech Inc., and Vice President, Global CMC Regulatory and Operations for Bristol-Myers Squibb.
Dr. Lloyd has a proven track record evidenced by her participation in the submission and marketing approval of over a dozen small molecule, biologic and biologic/device combination products in a wide variety of therapeutic areas including oncology, endocrinology/metabolism, antivirals, respiratory and psychiatric disorders.
Dr. Lloyd is Regulatory Affairs Certified (RAC) and has distinguished herself as a scientist with numerous awards and publications. She holds a Ph.D. in Molecular Genetics and Microbiology from Rutgers University and MDNJ. She was recognized by the Biomedical Engineering Department of Rutgers University with the 2003 Distinguished Alumni Award. Dr. Lloyd has also served as a member of the Industrial Advisory Board, Dept of Biomedical Engineering.
